Artwork

Content provided by The Lancet Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Lancet Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Sinisa Savic on treatment outcomes in VEXAS syndrome

12:07
 
Share
 

Manage episode 489160073 series 3294438
Content provided by The Lancet Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Lancet Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

In this podcast, Professor Savic talks about his recent publication that looks at treatment outcomes in patients with VEXAS syndrome, as well as what clinicians should look out for in patients (red flags), and future priorities for research.
VEXAS syndrome (short for Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome) was first described in 2020. It’s a rare, and often-life threatening, inflammatory condition primarily affecting men. It's caused by a mutation in the UBA1 gene, leading to systemic inflammation and progressive bone marrow failure. The condition can manifest with a variety of symptoms, including fevers, fatigue, rashes, and joint pain, and can affect various organs and tissues.

Read the full article:

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00034-7/fulltext?dgcid=buzzsprout_icw_podcast_June_25_lanrhe

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

  continue reading

24 episodes

Artwork
iconShare
 
Manage episode 489160073 series 3294438
Content provided by The Lancet Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Lancet Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

In this podcast, Professor Savic talks about his recent publication that looks at treatment outcomes in patients with VEXAS syndrome, as well as what clinicians should look out for in patients (red flags), and future priorities for research.
VEXAS syndrome (short for Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome) was first described in 2020. It’s a rare, and often-life threatening, inflammatory condition primarily affecting men. It's caused by a mutation in the UBA1 gene, leading to systemic inflammation and progressive bone marrow failure. The condition can manifest with a variety of symptoms, including fevers, fatigue, rashes, and joint pain, and can affect various organs and tissues.

Read the full article:

https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00034-7/fulltext?dgcid=buzzsprout_icw_podcast_June_25_lanrhe

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

  continue reading

24 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play